What is the U.S. Medical Eligibility Criteria category for the use of combined oral contraceptives during the first 21 days postpartum?

The correct category for the use of combined oral contraceptives during the first 21 days postpartum is categorized as 3 according to the U.S. Medical Eligibility Criteria (US MEC).

In this context, a category 3 indicates that the theoretical or proven risks usually outweigh the advantages of using the method. For combined oral contraceptives, the concern during the early postpartum period is primarily related to the increased risk of venous thromboembolism (VTE) due to physiological changes during pregnancy and the postpartum period. The recommendation is to consider balancing these risks with the benefits of effective contraception, which can vary depending on individual circumstances, including personal and family medical histories.

The other categories provide different evaluations of the safety of using contraceptive methods. Category 1 indicates no restrictions for the use of the method, while category 2 suggests that advantages generally outweigh theoretical or proven risks. On the other hand, category 4 reflects an unacceptable health risk if the method is used. Thus, category 3 emphasizes a cautious approach to prescribing combined oral contraceptives in the early postpartum phase while acknowledging that some women may still require contraception and should be carefully evaluated for individual risks and benefits.